Market revenue in 2023 | USD 425.7 million |
Market revenue in 2030 | USD 1,021.1 million |
Growth rate | 13.3% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase II |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 55.46% in 2023. Horizon Databook has segmented the Canada cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
According to Life Sciences in British Columbia: Sector Profile, published in June 2020, Canada is among the top three locations to conduct clinical trials globally. It states that multinational pharmaceutical companies conduct a large portion of their clinical trials in Canada, as the country has a world-class clinical trials environment.
The above factors are likely to contribute to Canada’s market growth over the forecast period. The initiative strengthens Canada’s position as a leader in regenerative medicines. Canadian incentive offers 15% non-refundable federal tax credit to CROs. The CRO is eligible for funding even if the sponsor is a foreign client.
Canadian CROs are expanding its presence in developing countries such as South and Central America to leverage from the market. Health Canada is a clinical trial database that provides information on Phase I, II, and III trials. This database helps the citizens look for a clinical trial relevant to their medical condition, and hence, facilitates easy patient recruitment and faster trial initiation.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Canada cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account